Welcome to our dedicated page for Amphastar Pharma SEC filings (Ticker: AMPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amphastar Pharmaceuticals filings document the regulatory disclosures of a Delaware biopharmaceutical company focused on generic and proprietary injectable, inhalation, and intranasal products, along with active pharmaceutical ingredient products. Form 8-K reports furnish operating results, product revenue commentary, non-GAAP measures, and material business updates tied to the company's pharmaceutical products business.
Amphastar's SEC filings also cover governance and capital-structure matters, including proxy disclosures, executive compensation, employment agreements, equity-compensation dilution, and share repurchase authorizations. Material agreement filings describe licensing rights for a corticotropin compound, supply arrangements involving a Chinese subsidiary, related-party review procedures, and commercial terms that affect the company's pipeline, manufacturing, and distribution activities.
Amphastar Pharmaceuticals reported sharply lower profitability for the quarter ended March 31, 2026 despite essentially flat sales. Net revenues were $171.2 million versus $170.5 million a year earlier, but net income fell to $6.4 million from $25.3 million as cost of revenues and operating expenses increased.
Gross profit declined to $70.3 million from $85.3 million, while research and development, general and administrative, and other costs all rose. Diluted earnings per share were $0.14 compared with $0.51. Operating cash flow improved to $47.8 million, and the company ended the quarter with $171.2 million in cash, cash equivalents, and restricted cash and total assets of $1.65 billion, including significant BAQSIMI® product rights.
Amphastar Pharmaceuticals reported first quarter 2026 results showing flat revenue but significantly lower profit. Net revenues were $171.2 million, essentially unchanged from $170.5 million a year earlier, while GAAP net income fell to $6.4 million from $25.3 million. GAAP diluted EPS declined to $0.14 from $0.51, and adjusted non-GAAP diluted EPS decreased to $0.42 from $0.74.
Gross profit dropped to $70.3 million from $85.3 million as gross margin narrowed to 41.1% from 50.0%, reflecting an 18% rise in cost of revenues. Research and development spending increased 33% to $26.7 million and general and administrative expense rose 13% to $18.0 million. Despite lower earnings, cash flow provided by operating activities was $47.8 million.
The company highlighted the approval and launch of Ipratropium Bromide HFA, an exclusive license for a fully synthetic corticotropin compound, and progress across a proprietary and biosimilar pipeline. Current filings include one ANDA and one biosimilar insulin candidate targeting markets over $1.6 billion, plus additional biosimilar and generic programs addressing several billion dollars of estimated market opportunity.
Amphastar Pharmaceuticals, Inc. is holding a virtual 2026 annual stockholder meeting on June 1, 2026 at 11:30 a.m. Pacific Time. Stockholders of record as of April 6, 2026, when 44,534,974 common shares were outstanding, can vote online, by phone, or by mail.
Investors will vote on electing three Class I directors to terms ending in 2029, ratifying Ernst & Young LLP as independent auditor for 2026, approving an advisory “say‑on‑pay” vote on executive compensation, and choosing how often future say‑on‑pay votes occur. The board recommends annual say‑on‑pay votes and supports all four proposals.
Amphastar Pharmaceuticals Inc received an amended Schedule 13G/A from The Vanguard Group reporting that Vanguard beneficially owns 0 shares of Amphastar common stock as disclosed in the amendment dated 03/13/2026 and signed 03/26/2026.
The filing explains this zero ownership reflects an internal realignment at The Vanguard Group, Inc.; certain subsidiaries or business divisions now report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment lists Vanguard's voting and dispositive powers as 0 and states Vanguard's aggregate ownership is 0% of the class.
Amphastar Pharmaceuticals director and EVP Liawatidewi Yakob reported a tax-withholding share disposition related to RSU vesting. On 2026-03-15, 1,033 shares of Common Stock were withheld at $18.18 per share to cover her tax liability from vested restricted stock units.
After this non-market tax-withholding event, she directly holds 121,892 shares of Amphastar Common Stock. An additional 2,459 shares are held indirectly by the Yakob and Sunmoon Trust dated July 25, 2013, for which she serves as a trustee.
Amphastar Pharmaceuticals senior executive Rong Zhou reported a routine tax-withholding share disposition tied to restricted stock units. On March 15, 2026, 1,225 shares of common stock were withheld at $18.18 per share to satisfy tax liabilities from RSU vesting.
After this transaction, Zhou directly held 171,554 Amphastar shares. Footnotes show additional indirect holdings of 99,668 shares held by the Zhou Family Trust, where Zhou serves as trustee, and 5,000 shares held by Zhou’s spouse.
Amphastar Pharmaceuticals CFO William J. Peters reported a routine tax-related share disposition. On the vesting of restricted stock units, 1,973 shares of common stock were withheld at $18.18 per share to satisfy his tax liability, rather than sold on the open market.
After this withholding, Peters directly holds 175,063 shares of Amphastar common stock. This filing reflects a compensation-driven, non-discretionary tax-withholding event, not an open-market purchase or sale decision.
Amphastar Pharmaceuticals reported insider share movements tied to routine tax withholding on vested restricted stock units. On the reported date, entities associated with executives Jack Y. Zhang and Mary Z. Luo delivered a total of 12,692 shares of common stock at $18.18 per share to satisfy tax liabilities, classified as tax-withholding dispositions rather than open-market sales.
Following these transactions, Zhang is shown holding 2,990,052 shares directly, while related entities report 6,827,679 shares held indirectly. Luo-related holdings include 1,245,125 shares held of record. These entries reflect compensation-related mechanics and leave substantial equity positions in place.
Amphastar Pharmaceuticals reported that its Board of Directors authorized a $50 million increase to the company’s share buyback program, effective March 12, 2026. The program is intended primarily to offset dilution from equity compensation grants over time.
Repurchases may occur over an indefinite period through open-market purchases, private block trades, Rule 10b5-1 plans, privately negotiated deals, or other methods permitted by law. The timing and actual number of shares bought back will depend on the share price, corporate and regulatory requirements, and other conditions.